ENTBF Stock Chart & Stats
$0.08
$0.08(63.18%)
At close: 4:00 PM EST
$0.08
$0.08(63.18%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.10
Previous CloseN/A
Volume3.65K
Average Volume (3M)2.06K
Market Cap
$589.72K
Enterprise Value$1.06
Total Cash (Recent Filing)$321.83K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta4.11
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding13,858,926
10 Day Avg. Volume889
30 Day Avg. Volume2,056
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.83
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no reported debt reduces ongoing interest obligations and lowers solvency risk, preserving flexibility to allocate capital to R&D or trials. Over 2–6 months this structural feature supports runway management and reduces refinancing pressure if losses continue.
Reduced Loss Magnitude In 2025A materially smaller loss in 2025 versus earlier extreme years signals improving cost structure or concentrated program spend. If sustained, this trend can extend runway and lower near-term funding needs, improving the firm's ability to progress clinical programs.
Focused Psychedelic Therapeutics PipelineA clear strategic focus on psychedelic-based therapeutics creates a distinct R&D niche and specialization. This concentrated expertise supports durable competitive positioning in clinical protocols and delivery approaches, aiding long-term program clarity and partnerability.
Bears Say
Zero Recent RevenueReporting zero revenue in the most recent period means no product cash inflows to fund operations. Long-term this forces reliance on external financing to sustain trials and operations, increasing execution and dilution risk if commercial validation remains absent.
Persistent Negative Cash FlowConsistent negative operating and free cash flow denotes structural cash burn tied to operations and R&D. Over months, this erodes liquidity, necessitates additional capital raises, and constrains the company’s ability to fund multi-stage clinical programs without dilution or partnership trade-offs.
Small, Volatile Equity BaseA limited and volatile equity base provides a weak buffer against continued losses and increases vulnerability to adverse shocks. Structurally, this limits financial flexibility for multi-year clinical development and raises the likelihood of accelerated fundraising under unfavorable terms.
Entheon Biomedical News
ENTBF FAQ
What was Entheon Biomedical’s price range in the past 12 months?
Entheon Biomedical lowest stock price was <$0.01 and its highest was $0.10 in the past 12 months.
What is Entheon Biomedical’s market cap?
Entheon Biomedical’s market cap is $589.72K.
When is Entheon Biomedical’s upcoming earnings report date?
Entheon Biomedical’s upcoming earnings report date is Oct 22, 2026 which is in 88 days.
How were Entheon Biomedical’s earnings last quarter?
Entheon Biomedical released its earnings results on Jul 20, 2026. The company reported $0.013 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Entheon Biomedical overvalued?
According to Wall Street analysts Entheon Biomedical’s price is currently Overvalued.
Does Entheon Biomedical pay dividends?
Entheon Biomedical does not currently pay dividends.
What is Entheon Biomedical’s EPS estimate?
Entheon Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entheon Biomedical have?
Entheon Biomedical has 13,858,926 shares outstanding.
What happened to Entheon Biomedical’s price movement after its last earnings report?
Entheon Biomedical reported an EPS of $0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Entheon Biomedical?
Currently, no hedge funds are holding shares in ENTBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Technical Analysis
BetterLife Pharma
―
HAVN Life Sciences
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―